Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma (SUP-R)

• ClinicalTrials.gov Identifier: NCT02555748
• Recruitment Status: Completed
• First Posted: September 22, 2015
• Last Update Posted: January 12, 2021
• Sponsor: Institut Claudius Regaud
• Collaborator: University Hospital, Bordeaux
• Information provided by (Responsible Party): Institut Claudius Regaud

Study Description

Brief Summary:

This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study.

Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma will enter the study in one of the two cohorts (115 patients will be treated by sunitinib and 99 patients will be treated by pazopanib).

The purpose of this study is to examine the feasibility of sunitinib and pazopanib dose individualisation based on therapeutic drug monitoring (TDM) and to assess the benefit of this approach in terms of tolerance and efficacy compared with the current empirical method based only on tolerance observation.

Condition or disease	Intervention/treatment	Phase
Metastatic Renal Cell Cancer	Drug: Pazopanib; Drug: Sunitinib	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 47 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
• Actual Study Start Date: November 17, 2015
• Actual Primary Completion Date: January 16, 2020
• Actual Study Completion Date: January 16, 2020

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Pazopanib; The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period). During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.	Drug: Pazopanib
Active Comparator: Sunitinib; Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks). During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.	Drug: Sunitinib

Outcome Measures

Primary Outcome Measures :

1. Part I: Pharmacokinetics - Pazopanib or Sunitinib plasma concentrations [ Time Frame: On day 1 and day 15 during cycle 1 and cycle 2 (cycle length is 6 weeks) ]
2. Part II: Tolerance - Proportion of patients without treatment discontinuation due to adverse event (AE) during the first year. [ Time Frame: 5.5 years ]
   This corresponds to the number of patients without treatment discontinuation due to AE among the total number of patients in each group.
3. Part II: Efficacy - Proportion of patients without progression at 1 year. This corresponds to the number of patients without progression at 1 year among the total number of patients in each group [ Time Frame: 5.5 years ]
4. Part I: Adverse Events according to NCI toxicity scale (version 4.03) [ Time Frame: 1.5 years ]

Secondary Outcome Measures :

1. Part I and II: Objective Response (e.g. Complete or Partial Response) [ Time Frame: 5.5 years ]
   Objective Response will be defined using RECIST Criteria version 1.1.
2. Part I and II:- Progression free survival. [ Time Frame: 5.5 years ]
   Progression free survival is defined as the time from inclusion until progression (RECIST Criteria version 1.1) or death. Patients alive at last follow-up news are censored at this date.
3. Part I and II: Safety according to the classification of the NCI: Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.03. [ Time Frame: 5.5 years ]
4. Part I and II: Hand-foot syndrome (HFS) [ Time Frame: 5.5 years ]
   Hand-foot syndrome (HFS) will be evaluated using the HFS-14 questionnaire. This scale specifically developed for patients with HFS is a valid and valuable tool for measuring HFS-related QoL impairment.
5. Part I and II: Quality of life using the quality of life questionnaire (QLQ)-C30 [ Time Frame: 5.5 years ]
   Quality of life will be evaluated using the QLQ-C30 questionnaire

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma.
2. Measurable tumours as defined by RECIST criteria version 1.1.
3. Age ≥ 18 years old.
4. WHO Performance Status ≤ 2.
5. Life expectancy ≥ 6 months.
6. Adequate cardiac function (baseline Left Ventricular Ejection Fraction (LVEF) ≥ 50% determined by Multiple Gated Acquisition scan (MUGA) or echocardiography) and pulmonary function.
7. Renal function defined as creatinine clearance (Cockcroft and Gault formula) > 30 mL/min.
8. Adequate liver function defined as: total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN); Alanine AminoTansferase (ALAT) and Aspartate AminoTransferase (ASAT) ≤ 2.5 x ULN; Concomitant elevation in bilirubin and ASAT/ALAT above 1.0 x ULN is not allowed.
9. Patients must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up.
10. Negative pregnancy test for women in childbearing potential.
11. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study (before study entry and until 30 days after the last administration of study treatment).
12. Patients affiliated to a social health insurance.

Exclusion Criteria:

1. Patients without any venous access for blood sampling.
2. Hypersensitivity to the active substance or to any of the excipients.
3. History or clinical evidence of central nervous system (CNS) metastases, except for individuals who have previously-treated CNS metastases.
4. Corrected QT interval (QTc) > 480msecs using Bazett's formula.

5. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to:

   • Uncontrolled infection.
   • Cardiovascular conditions within the last 6 months such as cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New-York Heart Association (NYHA), clinically significant irregular heartbeat requiring medication.
   • Poorly controlled hypertension [defined as systolic blood pressure of ≥140 mmHg or diastolic pressure of ≥90 mmHg).
   • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months.

   Note: patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.

6. Evidence of active bleeding or bleeding diathesis.
7. Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cytochrome P450 isoenzyme 3A4 (CYP3A4) within the last 14 days prior to inclusion and/or during the study.
8. Patients already treated with an anticancer treatment in the previous four weeks or patient requiring anticancer treatment during the study (chemotherapy, immunotherapy, hormonotherapy, radiotherapy or surgery).
9. Pregnant or breast-feeding women.
10. Positive diagnostic of HIV, B and C hepatitis.
11. Patients with serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety, provision of informed consent, or compliance to study procedures.
12. Patients who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Contacts and Locations

Locations

France

CHU DE BORDEAUX - Hôpital Saint-André

Bordeaux, France, 33035

Institut Bergonie

Bordeaux, France, 33076

CHU DE LIMOGES - Hôpital Dupuytren

Limoges, France, 87042

Centre Leon Berard

Lyon, France, 69373

Institut Paoli Calmettes

Marseille, France, 13273

Institut Regional Du Cancer Montpellier

Montpellier, France, 34298

CH RODEZ

Rodez, France, 12027

Institut Claudius Regaud

Toulouse, France, 31059

Sponsors and Collaborators

Institut Claudius Regaud

University Hospital, Bordeaux

Investigators

• Principal Investigator: Christine CHEVREAU, MD; IUCT-O

More Information

• Responsible Party: Institut Claudius Regaud
• ClinicalTrials.gov Identifier: NCT02555748
• Other Study ID Numbers: 14 URO 06
• First Posted: September 22, 2015
• Last Update Posted: January 12, 2021
• Last Verified: January 2021

Additional relevant MeSH terms:

Carcinoma, Renal Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Sunitinib; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action